| Bioactivity | MTX-3937 is a Siglec-9 inhibitor with a Kd value of 3.15 μM. MTX-3937 enhances the functions and homeostasis of natural killer (NK) cells. MTX-3937 remarkably improves NK cell-mediated anti-tumor efficacy against liver cancer in vivo[1]. |
| Invitro | MTX-3937 (5-20 μM; 24 小时) 增强 NK92 细胞对 K562 细胞和 HepG2-Luc 细胞的杀伤活性[1]。MTX-3937 (5-20 μM; 24 小时) 以剂量依赖性方式显著增强 NK92 细胞和人外周 NK 细胞中 CD107a、TNF-α 和 IFN-γ 的产生[1]。MTX-3937 (5-20 μM; 24 小时) 抑制 Siglec-9 和下游 SHP1 和 SHP2 的磷酸化[1]。 NK92 cells5 μM, 10 μM, and 20 μM24 hoursSuppressed the phosphorylation level of both SHP1 and SHP2 in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> MTX-3937 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | MTX-3937 处理的 NK92 细胞（20 μM；24 小时）随时间显著抑制腹膜肝癌异种移植瘤的生长。单独使用 MTX-3937 不会影响肿瘤生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 305866-91-5 |
| Formula | C33H21ClO5 |
| Molar Mass | 532.97 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rong Xiao, et al. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy. J Hepatol. 2024 May;80(5):792-804. |